Chronic Achilles tendinopathy: shockwaves added to exercise · Randomized trial · 2008
Does adding shockwave to exercise help Achilles tendon pain?
In this trial, adding four weekly shockwave sessions to stretching and heel-drop exercises gave a higher ankle and foot score than sham at three months: about 89 vs 79 out of 100. Pain on walking, stairs and running fell in both groups, and the difference between them was not statistically clear.
Helped foot scores more than sham + exercise- adults with Achilles tendon pain
- 48
- sessions, one a week
- 4
- followed up
- 3 mo
Good to know: Both groups also did the same stretching and heel-drop exercises.
Rasmussen S, Christensen M, Mathiesen I, et al. Acta Orthopaedica, 2008 · Read the paper ↗
How this study worked
What happened
difference between the groups, 95% CI 3.2 to 15.8 Ankle and foot score vs sham · points on the 0–100 ankle and foot score · 3 months (12 weeks)
Ankle and foot score vs sham
Difference in AOFAS score (0–100), with likely range · 0 means no difference
Show the numbers
| Difference (points on the 0–100 ankle and foot score) | likely range | |
|---|---|---|
| At 3 months | +10 | 3.2 to 15.8 |
The treatment
Shockwaves plus exercise
Shockwave, once a week for 4 weeks
- Sessions
- 4, one a week
- Pulses
- 2,000 per session
- Strength
- 0.12–0.51mJ/mm² · 50 per second
- Numbing
- None
- Device
- Piezoson 100
- Everyone also got
- Stretching and eccentric (heel-drop) exercises at each visit
Compared with: Sham shockwave plus the same stretching and heel-drop exercises
Settings are what each study used, not a prescription.
This protocol among the library’s
Each dot is a group treated with shockwaves in a study in this library, at the midpoint when the paper gave a range. The dark dots are this study.
Of the other 69 groups: 15 lower, 29 the same, 25 higher.
Of the other 78 groups: 54 lower, 12 the same, 12 higher.
Who took part
48 adults aged 19–80 with Achilles tendon symptoms for over 3 months, at a Danish hospital; the part of the tendon affected was not stated.
Side effects
The study does not report side effects.
All the numbers and the full appraisal
The results, in numbers.
Forty-eight adults (mean age 47, range 19–80) with Achilles tendinopathy symptoms for over three months, diagnosed clinically at Aalborg Hospital, with full working capacity. Insertional versus midportion location was not specified. Table 1 lists 20 men and 28 women; the abstract and text say 28 men.
All 24 received four sessions; 24 examined at 4 weeks, 23 at 8 weeks (one excluded after knee arthroscopy) and 22 at 12 weeks (one refused). Intention-to-treat used data until censoring.
All 24 received four sessions; one lost after a change of address, leaving 23 at 4, 8 and 12 weeks. Intention-to-treat used data until censoring.
AOFAS score, start to end5 reported outcomes
AOFAS score, start to end
AOFAS ankle-hindfoot score Points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Shockwaves plus exercise | — | 70 (SD 6.8) | 88 (SD 10) |
| Sham plus exercise | — | 74 (SD 12) | 81 (SD 16) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Change over time, shockwaves plus exercise versus sham plus exercise
AOFAS improved in both groups, more with active treatment (70 to 88) than with sham (74 to 81); the group-by-time contrast reached p=0.05. Sham started 4 points higher, which narrows the room to improve on a 100-point ceiling.
Analysis details and source
The paper does not label the time point of the 88 and 81 values or give the follow-up n for them; 22 active and 23 sham patients were examined at 12 weeks. The AOFAS scale combines function (50 points), pain (40) and alignment (10); 100 is the best result. Means and SD as reported.
AOFAS between groups at 8 weeks
AOFAS ankle-hindfoot score Points
Shockwaves plus exercise versus sham plus exercise
The paper reports better AOFAS results with active treatment at 8 weeks (p=0.01); group values at this visit are shown only in Figure 2.
Analysis details and source
No group means or interval are given in the text for this visit; values were not read off the figure.
AOFAS between groups at 12 weeks
AOFAS ankle-hindfoot score Points
Shockwaves plus exercise versus sham plus exercise
The paper reports better AOFAS results with active treatment at 12 weeks (p=0.04).
Analysis details and source
Group means at 12 weeks are not separately tabulated; see the adjusted three-month analysis.
AOFAS adjusted at 3 months
AOFAS ankle-hindfoot score Points
Shockwaves plus exercise versus sham plus exercise
Analysis of covariance of change from before treatment to 3-month follow-up; intention to treat with data until censoring
After adjustment, the active group averaged 10 AOFAS points higher than sham at three months (95% CI 3.2 to 15.8; p=0.006). The trial was powered to detect a 10-point difference, which the authors treated as the minimal relevant difference.
Analysis details and source
Group values are adjusted estimated marginal means with 95% intervals, not raw follow-up means. The interval around 89 (85–95) is asymmetric as printed.
AOFAS in women (post hoc)
AOFAS ankle-hindfoot score Points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Shockwaves plus exercise | — | — | 91 (SD 10) |
| Sham plus exercise | — | — | 77 (SD 18) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Women: shockwaves plus exercise versus sham plus exercise
In an analysis that was not preplanned, women scored 91 with active treatment versus 77 with sham at three months (p=0.05); in men the scores were similar. Post hoc subgroups can arise by chance.
Analysis details and source
Subgroup sizes are not given; because Table 1 and the text disagree on the sex split, the number of women per arm is uncertain.
Pain on four activities1 reported outcome
Pain on four activities
VAS pain on walking, walking upstairs, working and running VAS
Pain fell in both groups, with no statistically significant difference between groups for any of the four activities. The authors describe no supplementary effect of shockwaves on pain.
Analysis details and source
No numerical between-group estimate or p-value is given. Table 1 baseline pain values (for example 35 and 34 for working) appear to use a 0–100 scale, while Figure 4 plots 0–10; the scale is not stated.
How treatment was delivered
Piezoson 100, 2,000 shots per session at 0.12–0.51 mJ/mm² and 50 Hz, once weekly for four weeks, applied with the patient prone to the area of swelling and tenderness, after stretching and eccentric training. No local anaesthesia and no ultrasound guidance. The paper calls these radial shock waves; the Piezoson 100 name suggests a piezoelectric focused source (extractor note), so the modality is uncertain.
2,000 shots at 0 mJ/mm² and 50 Hz at the same four sessions; patients lay prone, could not see the machine and heard the same ticking sound. Treatment was given by a person not involved in the study design.
Both groups received stretching exercises and eccentric training at four outpatient sessions over four weeks, before the active or sham application.
Computer-generated list concealed in numbered envelopes; patients and the outcome assessor were blinded. Sham credibility was not tested.
The paper does not report adverse events or side effects for either group; unreported is not the same as none. No competing interests were declared; the funding source is not stated.
Sex distribution conflicts: Table 1 gives 8/16 (control) and 12/12 (intervention) men/women, i.e. 20 men, while the abstract and Methods say 28 men. The authors also discuss more women in the control group.
Modality is unclear: the text describes radial shock waves at 50 Hz from a Piezoson 100, a device name that suggests a piezoelectric focused source (extractor interpretation). The energy range 0.12–0.51 mJ/mm² was wide and the target was the area of swelling without imaging guidance.
Losses are described inconsistently: the text says one exclusion and two missed 3-month visits during follow-up, whereas Figure 1 places the change-of-address loss before the 4-week examination. Censored data were carried into the intention-to-treat analysis without a stated method.
The primary group-by-time contrast was borderline (p=0.05), the time point of the 88 versus 81 values is not labelled, and multiple pairwise comparisons were made. The authors note that AOFAS includes alignment and hindfoot items that tendon treatment may not change and has a ceiling; no Achilles-specific score such as VISA-A was used.
Single centre, 12 weeks of follow-up, tendon site (insertional or midportion) and imaging not reported, harms not reported, and a post hoc sex subgroup. The registration identifier given (ON-007-01-RAS) is not a standard ClinicalTrials.gov number and was not checked. The authors themselves concluded that ESWT could not yet be recommended without further trials.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Sex distribution conflicts: Table 1 gives 8/16 (control) and 12/12 (intervention) men/women, i.e. 20 men, while the abstract and Methods say 28 men. The authors also discuss more women in the control group.
- Modality is unclear: the text describes radial shock waves at 50 Hz from a Piezoson 100, a device name that suggests a piezoelectric focused source (extractor interpretation). The energy range 0.12–0.51 mJ/mm² was wide and the target was the area of swelling without imaging guidance.
- Losses are described inconsistently: the text says one exclusion and two missed 3-month visits during follow-up, whereas Figure 1 places the change-of-address loss before the 4-week examination. Censored data were carried into the intention-to-treat analysis without a stated method.
- The primary group-by-time contrast was borderline (p=0.05), the time point of the 88 versus 81 values is not labelled, and multiple pairwise comparisons were made. The authors note that AOFAS includes alignment and hindfoot items that tendon treatment may not change and has a ceiling; no Achilles-specific score such as VISA-A was used.
- Single centre, 12 weeks of follow-up, tendon site (insertional or midportion) and imaging not reported, harms not reported, and a post hoc sex subgroup. The registration identifier given (ON-007-01-RAS) is not a standard ClinicalTrials.gov number and was not checked. The authors themselves concluded that ESWT could not yet be recommended without further trials.
Source-linked critical reading
Double-blind sham-controlled randomized trial in Denmark; computer-generated list concealed in numbered envelopes. Forty-eight randomized, 24 per group; 22 active and 23 sham patients were examined at 12 weeks.
In this trial, adding four shockwave sessions to stretching and eccentric exercise led to a higher ankle and hindfoot score (function, pain and alignment) than sham at three months. Pain on walking, stairs, work and running fell in both groups, and the difference between groups was not statistically significant. Follow-up ended at three months.
Does adding shockwaves to stretching and eccentric training improve chronic Achilles tendinopathy more than a sham application?
Double-blind, sham-controlled randomized trial at Aalborg Hospital, Denmark (2004–2005). Of 66 people assessed, 51 were eligible; three chose their own treatment and 48 were randomized, 24 per group, by a computer-generated list concealed in numbered envelopes. Patients and assessor were blinded. At 12 weeks 22 active and 23 sham patients were examined; analysis was by intention to treat using data until censoring.
Forty-eight adults (mean age 47, range 19–80) with Achilles tendinopathy symptoms for over three months, diagnosed clinically at Aalborg Hospital, with full working capacity. Insertional versus midportion location was not specified. Table 1 lists 20 men and 28 women; the abstract and text say 28 men.
Piezoson 100, 2,000 shots per session at 0.12–0.51 mJ/mm² and 50 Hz, once weekly for four weeks, applied with the patient prone to the area of swelling and tenderness, after stretching and eccentric training. No local anaesthesia and no ultrasound guidance. The paper calls these radial shock waves; the Piezoson 100 name suggests a piezoelectric focused source (extractor note), so the modality is uncertain.
Sham sessions used the same 2,000 shots at 0 mJ/mm² with the machine out of sight and the same ticking sound. Both groups did stretching and eccentric training at the same four weekly visits, so the trial tests shockwaves added to exercise.
The primary outcome was the AOFAS ankle-hindfoot score (function 50, pain 40, alignment 10; 100 best), measured before, during the four treatment weeks and at 4, 8 and 12 weeks. VAS pain on walking, stairs, working and running was recorded at each visit. The trial was powered for a 10-point AOFAS difference.
AOFAS rose from 70 (SD 6.8) to 88 (10) with active treatment and from 74 (12) to 81 (16) with sham; the change over time differed at p=0.05. Groups differed at 8 weeks (p=0.01) and 12 weeks (p=0.04). Adjusted three-month means were 89 versus 79, a difference of 10 points (95% CI 3.2 to 15.8; p=0.006). Pain fell in both groups with no significant between-group difference. A post hoc analysis found the AOFAS difference in women (91 versus 77, p=0.05), not in men.
The paper does not report adverse events or side effects for either group; unreported is not the same as none. No competing interests were declared; the funding source is not stated.
Table 1 lists 20 men while the abstract says 28; the paper calls the waves radial but names a Piezoson 100, so the modality is uncertain; text and Figure 1 describe one loss at different times. The main contrast was borderline, the AOFAS score was not designed for Achilles tendinopathy, tendon site and imaging were not reported, follow-up lasted 12 weeks and the sex subgroup was post hoc.
Applies to adults with clinically diagnosed chronic Achilles tendinopathy doing supervised stretching and eccentric training. It does not show a pain benefit, an effect beyond three months, or which tendon site or device setting responds.
A larger blinded trial should report tendon site, imaging, energy and device type, use a tendon-specific score such as VISA-A, prespecify pain and function outcomes, record harms and follow patients beyond one year.
Read the original article.
Shockwave therapy for chronic Achilles tendinopathy: a double-blind, randomized clinical trial of efficacy.
Rasmussen S, Christensen M, Mathiesen I, Simonson O. · Acta orthopaedica · 2008
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →